Back to news

Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement

Globe Newswire•16/11/2026•16:01 ET
0

Key Highlights

  • ➤DARE to PLAY prescriptions written across 48 states and Washington, D.C.
  • ➤Flora Sync LF5 orders span 27 states, with first provider reorder
  • ➤Daré secured more than $75 million in non-dilutive grant awards
  • ➤DARE-LARC1 grant funding reached approximately $43.3 million of potential $49.0 million
  • ➤Third-quarter revenue rose to approximately $48,000; net loss narrowed to approximately $3.2 million

Expert Statements

Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Daré Bioscience

“This is an exciting day for clinicians and women waiting for DARE to PLAY Sildenafil Cream, as the first shipment is on route from the outsourcing facility to Medvantx, the central pharmacy that handles order processing and dispensing. DARE to PLAY provider engagement built demand ahead of dispensing, with prescriptions written across 48 states and Washington, D.C. Our outsourcing facility partner has been working to manufacture supply at a scale to meet anticipated demand, and, with product now on route to Medvantx, we expect prescription dispensing to commence later this month.”

Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Daré Bioscience

“For Flora Sync LF5 we built our initial commercial approach around the relationships women have with their healthcare providers, given the clinical data that distinguish Flora Sync LF5 in the category, and the early response to Flora Sync LF5 is encouraging. Recommendations and sampling are helping women discover the product, while our provider office reorder gives us an early indication of repeat demand”

Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Daré Bioscience

“Our priority now is to build on that response and turn initial purchases into sustained growth. We look forward to launching Flora Sync LF5 on Amazon in early 2027, and are pleased to be expanding the DARE to RESTORE™ brand family to include Flora Renew™ and Flora Reset™, a vulvar mask and cleanser, also anticipated in early 2027.”

Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Daré Bioscience

“Non-dilutive funding is central to how we develop our pipeline. We have secured more than $75 million in grant awards to provide funding support for our programs that does not dilute our shareholders, and we continue to pursue additional funding opportunities”

Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Daré Bioscience

“That investment is also creating opportunities beyond the programs it initially supported. DARE-IDDS, our programmable drug delivery technology underlying our DARE-LARC1 contraceptive program, is designed to control how much drug is released and when. This tunability has potential applications in obesity, diabetes, hormone therapies and neurological diseases. We are exploring potential strategic collaborations for the platform into these areas, with the goal of reducing the burden of frequent injections or daily dosing.”

DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington, D.C.

Commercial launch of Flora Sync LF5™ showing encouraging early indicators, including orders from 27 states, provider office reorder and positive consumer feedback

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in